Dear Editor,
Onconase, the smallest member of RNase A super family that was isolated from oocytes or early embryos of the Northern Leopard Frog (Rana pipiens), has been granted as an orphan drug for the treatment of malignant mesothelioma by US FDA [1, 2] . It was also tested in clinical trials for patients with non-small-cell lung cancer, breast cancer, and renal cell cancer [2] . Onconase is extremely stable with a Tm of ∼87 °C, resists degradation by various proteases, and evades ribonulease inhibitors (RI) present in mammalian cell cytosol [3] [4] [5] , which confers advantages to its application in cancer treatment. More importantly, onconase specifically induces apoptosis of cancer cells but has low cytotoxicity to their normal counterparts [2] . One rational hypothesis for this selectivity is that onconase, a highly cationic protein with calculated pI > 9.5, is selectively internalized by tumor cells given that tumor cells generally are more negatively charged than cognate normal cells [2] . Nevertheless, as an anti-cancer drug, the mechanisms of its antitumor activity are not well understood. The current model of onconase-mediated cytotoxicity favors that onconase degrades tRNAs in tumor cells after its cytosolic internalization, which leads to ubiquitous inhibition of protein synthesis and apoptosis [2] . However, increasing evidence indicates that degradation of tRNAs and inhibition of protein synthesis are not the sole cause of onconase-induced apoptosis [6] [7] [8] . Consistent with the welldocumented causal roles of microRNAs (miRNAs) in cancers, a recent study indicates that onconase regulates the expression of miRNAs in malignant pleural mesothelioma cell lines (H2959, H2373, and H2591), and reveals that onconase controls cell proliferation, invasion, migration, and apoptosis through modulating miRNAs [9] . However, how onconase affects miRNA expression remains unclear. Here our biochemical studies showed that miRNAs are the direct downstream RNA species of onconase. Intriguingly, we found that onconase downregulates miRNAs by cleavage of miRNA precursors, thus reducing the amount of mature miRNAs produced from Dicer processing.
Using recombinant onconase that was prepared as described previously [10] , we found that miR-155 and miR-21, two well-known oncogenic miRNAs with high endogenous levels in mesothelioma cell line Msto-211h, were dose-and time-dependently downregulated by onconase in these cells (Supplementary information, Figure  S1A , S1B, S1D and S1E), accompanied by a significant upregulation of their respective targets examined, including miR-155 targets SOCS1 [11] , C/EBPβ [12, 13] , and ETS-1 [14] , and miR-21 targets PTEN [15] and PDCD4 [16] (Supplementary information, Figure S1C and S1F). Furthermore, our miRNA microarray assays showed that the majority of miRNAs in Msto-211h cells were significantly downregulated by onconase (Supplementary information, Figure S2A ), while our quantitative realtime PCR (qRT-PCR) assays validated the onconasemediated downregulation of let-7 family miRNAs, miR-21, miR-29a, miR-92a, miR-92b, miR-155, miR-221, and miR-222 (Supplementary information, Figure S2B ). These results indicate that miRNA expression is susceptible to onconase, consistent with the recent report [9] . However, different from the findings of upregulation of 5 miRNAs in addition to downregulation of the majority in mesothelioma cells by onconase in that study [9] , we found that onconase appears to globally downregulate miRNAs in Msto-211h cells. This dissimilarity is likely due to a different cell line examined in this study. Nevertheless, our microarray assays also showed that four miRNAs (miR-181a, miR-30a, miR-1280, and miR-720) were upregulated by onconase treatment (Supplementary information, Figure S2A) ; however, further analyses revealed that all these four miRNAs showed low intensities in microarray assays (Supplementary information, Figure S2C) . Moreover, our qRT-PCR assays showed that miR-181a expression was actually reduced > 2-fold by onconase treatment (Supplementary information, Figure  S2B ), while the other three miRNAs were undetectable in qRT-PCR assays (data not shown), implicating low endogenous levels of these miRNAs in Msto-211h cells and false positive in microarray assays. It is noteworthy that 4 out of 5 upregulated miRNAs have extremely low values of intensities in their miRNA microarray data [9] , while all of these five upregulated miRNAs do not meet the cutoff of mean intensities above 500 in our microarray assays.
We next asked how onconase downregulates miRNAs. To this end, we performed in vitro onconase reactions to examine the effect of onconase on chemically synthesized 23-nt mature miR-155 and 65-nt pre-miR-155 strands (Supplementary information, Data S1). A human tRNA Arg , which was transcribed by T7 RNA polymerase in vitro, was used as a positive control for onconase activity. We found that this tRNA strand was strongly degraded by onconase ( Figure 1A , lane 5), indicating that onconase prepared in the lab is highly active. Interestingly, we found that miR-155 precursor strand was Figure 1A, lane 3) , while mature miR-155 strand was marginally affected ( Figure 1A, lane 7) , suggesting that onconase preferentially degrades the precursor forms of miRNAs. To further corroborate this, we examined the effect of onconase on other miRNAs. Consistently, we found that onconase strongly degraded the precursor strands of miR-21 and miR-29a, but mildly affected their mature forms ( Figure  1B) . These results together indicate that oncoanse preferentially degrades miRNA precursors instead of the mature forms of miRNAs. Given that onconase preferably cleaves miRNA precursors ( Figure 1A and 1B) and that miRNA precursors are processed into miRNAs by Dicer in cells, we speculated that onconase might reduce miRNA expression through disturbing Dicer-mediated mature miRNA production in cancer cells. Indeed, using in vitro Dicer processing analyses (Supplementary information, Data S1), we found that processing of pre-miR-21 into mature miR-21 by Dicer was dose-dependently reduced by onconase ( Figure 1C ). These results suggest that onconase degrades miRNA precursors and subsequently results in less production of mature miRNAs produced by Dicer.
Finally, we mapped the cleavage sites of onconase in miRNA precursors. Using primer extension analyses (Supplementary information, Data S1), we found that pre-miR-155 was mainly cleaved at C Figure 1F ). These results indicate that onconase appears to predominantly cleave miRNA precursors at UG and UU residues, which are similar to the cleavage specificity of onconase observed in tRNAs [17] .
In summary, our results indicate that onconase ubiquitously downregulates miRNA expression in mesothelioma cells. Interestingly, our biochemical assays reveal that onconase preferentially degrades miRNA precursors and mildly affects mature forms of miRNAs. Given that miRNA precursors resemble tRNAs, the well-documented downstream RNA species of onconase, with ∼70-nt long and hairpin structure, we speculate that an appropriate secondary structure might be required for onconase substrates. Indeed, similar to the predominant cleavages of onconase in tRNAs located in the variable loop or stem of D-arm [17] , we found that the cleavage sites of onconase in miRNA precursors are mapped at both loop and stem regions. Given that oncogenic miRNAs are upregulated in cancer cells while tumor suppressive miRNAs are often downregulated [18] , it is likely that onconase exerts its antitumor activity through targeting miRNAs, i.e., mainly oncogenic miRNAs. Taken together, our study reveals miRNA precursors as a novel class of RNA targets for onconase in addition to tRNAs, bringing new insights into the mechanisms of onconasemediated cytotoxicity in cancer cells.
